Slide 1: FY23 AGM Presentation and Update
FY23 AGM Presentation and Update ASX: UCM • MedTech in active growth phase • Products and markets • Partnerships • Rebound ready • Prepared for strategic restructure Prof. Rob Phillips Chairman and CEO, Uscom Limited Oct 26, 2023
Slide 2: Uscom Vision
Uscom Ltd I FY2023 Annual General Meeting I uscom.com.au Chair's Update Uscom Overview FY23 Results Uscom Markets Milestones FY24 Outlook Uscom Vision “A great company, with great vision, technology and culture, and a great global commercial opportunity” A Company for the Future Clinical Mission - T
Slide 3: Uscom Value
Uscom Ltd I FY2023 Annual General Meeting I uscom.com.au Chair's Update Uscom Overview FY23 Results Uscom Markets Milestones FY24 Outlook Uscom Value Advanced Global Medtech Company Impending value drivers Great company, vision, technology, culture Foxconn partnership, new products, US and global op
Slide 4: Uscom Medical Technology
Uscom Ltd I FY2023 Annual General Meeting I uscom.com.au Chair's Update Uscom Overview FY23 Results Uscom Markets Milestones FY24 Outlook Uscom Medical Technology Future growth from expanding products and global operations World leading medical technology (ASX:UCM) with global footprint – Sydney, Si
Slide 5: FY23 Results
Uscom Ltd I FY2023 Annual General Meeting I uscom.com.au Chair's Update Uscom Overview FY23 Results Uscom Markets Milestones FY24 Outlook FY23 Results Returning to growth UCM Total Receipts Trend FY12 – FY24* $2.18 million $3.30 million 51% Cash on Hand Total Receipts H2 > H1 Building the future Res
Slide 6: FY23 Results - H2
FY21 Results Uscom Ltd I FY2023 Annual General Meeting I uscom.com.au Chair's Update Uscom Overview FY23 Results Uscom Markets Milestones FY24 Outlook FY23 Results – H2 A tale of two halves UCM FY2023 Results H1 v H2 $2.18 million $1.19 million $1.84 million Cash on Hand Q4 sales H2 receipts 2 1.9 1
Slide 7: FY23 Results - Q4
FY21 Results Uscom Ltd I FY2023 Annual General Meeting I uscom.com.au Chair's Update Uscom Overview FY23 Results Uscom Markets Milestones FY24 Outlook FY23 Results – Q4 Quarter and Half Growth $2.18 million $1.19 million $1.84 million UCM Q4 Sales FY12 – FY23 Cash on Hand Q4 sales H2 receipts Buildi
Slide 8: FY23 Results - by Region
Uscom Ltd I FY2023 Annual General Meeting I uscom.com.au Chair's Update Uscom Overview FY23 Results Uscom Markets Milestones FY24 Outlook FY23 Results - by Region Uscom Total Revenue by Region – FY 2023 Uscom Total Revenue by Region Asia - $0.90 million Europe - $0.97 million Sales reduced 34% due t
Slide 9: Products and Markets
Uscom Ltd I FY2023 Annual General Meeting I uscom.com.au Chair's Update Uscom Overview FY23 Results Uscom Markets Milestones FY24 Outlook Products and Markets High value technologies - large markets - strong predicted growth 3 high value product divisions – cardiac, hypertension/vascular and pulmona
Slide 10: SpiroSonic AIR
FY21 Results Uscom Ltd I FY2023 Annual General Meeting I uscom.com.au Chair's Update Uscom Overview FY23 Results Uscom Markets Milestones FY24 Outlook SpiroSonic AIR Next generation spirometry “Hospital in Home” – Asthma, COVID, COPD and Occupational Lung disease Applications - Research/CRO, hospita
Slide 11: International Brands and eHealth
Uscom Ltd I FY2023 Annual General Meeting I uscom.com.au Chair's Update Uscom Overview FY23 Results Uscom Markets Milestones FY24 Outlook International Brands and eHealth Uscom Group International Brands 5 great International Brands across 3 product divisions International Brand Branding Sector Usco
Slide 12: Global Approvals
Uscom Ltd I FY2023 Annual General Meeting I uscom.com.au Chair's Update Uscom Overview FY23 Results Uscom Markets Milestones FY24 Outlook Global Approvals Regulatory approvals proceeding Regulatory Approvals China SE Asia Euro US Russia ROW 23/24 USCOM 1A New New 23/24 BP+ ✓ ✓ 23/24 New 23/24 SpiroS
Slide 13: IP Value
Uscom Ltd I FY2023 Annual General Meeting I uscom.com.au Chair's Update Uscom Overview FY23 Results Uscom Markets Milestones FY24 Outlook IP Value Global Assets Revenue protection Next Generation Products Registered IP Uscom Ltd Uscom China Uscom Kft Total USCOM 1A 115 33 - 148 BP+ 10 - - 10 SpiroSo
Slide 14: Publications - Clinical value
Uscom Ltd I FY2023 Annual General Meeting I uscom.com.au Chair's Update Uscom Overview FY23 Results Uscom Markets Milestones FY24 Outlook Publications – Clinical value Uscom - leader in world cardiovascular and pulmonary science >1,000 Peer reviewed publications 3 Global Guidelines Applications Emer
Slide 15: Uscom Devices in World's Best Hospitals
Uscom Ltd I FY2023 Annual General Meeting I uscom.com.au Chair's Update Uscom Overview FY23 Results Uscom Markets Milestones FY24 Outlook Uscom Devices in World’s Best Hospitals Europe – Slovenjia – Lubiana Asia - China - Europe - Poland – Chongqing University Medical Center Lodz PERIN Chongqing Asi
Slide 16: Chinese Domestic Manufacture - BMPA
Uscom Ltd I FY2023 Annual General Meeting I uscom.com.au Chair's Update Uscom Overview FY23 Results Uscom Markets Milestones FY24 Outlook Chinese Domestic Manufacture - BMPA Chinese regulatory approval for Uscom and Foxconn Beijing Medical Products Authority • BMPA - Beijing branch of NMPA • Oversee
Slide 17: FY23 Achievements
Uscom Ltd I FY2023 Annual General Meeting I uscom.com.au Chair's Update Uscom Overview FY23 Results Uscom Markets Milestones FY24 Outlook FY23 Achievements Singapore Regional HQ Regional HQ activities expanded Singapore Capital opportunities under evaluation US Regulatory Emerging commercial centre
Slide 18: FY23 Capital Initiatives
FY21 Results Uscom Ltd I FY2023 Annual General Meeting I uscom.com.au Chair's Update Uscom Overview FY23 Results Uscom Markets Milestones FY24 Outlook FY23 Capital Initiatives 13 Month UCM Share trend 0.12 Addressing Market Value 0.11 A difficult year for markets 0.1 0.09 -51% Illiquidity combined w
Slide 19: Revenue Growth
Uscom Ltd I FY2023 Annual General Meeting I uscom.com.au Chair's Update Uscom Overview FY23 Results Uscom Markets Milestones FY24 Outlook Revenue Growth Cardiac BP and Vascular Pulmonary Products: USCOM 1A Products: BP+ & BP+ Reporter Products: SpiroSonic FLO, SMART, MOBILE, SpiroReporter New Produc
Slide 20: FY24 Regional Growth Strategy
Uscom Ltd I FY2023 Annual General Meeting I uscom.com.au Chair's Update Uscom Overview FY23 Results Uscom Markets Milestones FY24 Outlook FY24 Regional Growth Strategy Australia Singapore China Hungary UK US Uscom SE Asia Uscom China Singapore HQ operational hub linking SE Asia, China Initiate domes
Slide 21: Looking forward
Uscom Ltd I FY2023 Annual General Meeting I uscom.com.au Chair's Update Uscom Overview FY23 Results Uscom Markets Milestones FY24 Outlook Looking forward “Vision, technology, culture, and a unique global opportunity” A rare combination of international tailwinds behind an established and de-risked M
Slide 22: Summary
Uscom Ltd I FY2023 Annual General Meeting I uscom.com.au Chair's Update Uscom Overview FY23 Results Uscom Markets Milestones FY24 Outlook Summary “A rare combination of international tailwinds behind an established and de-risked MedTech enterprise offers growth opportunities for FY24 and the future”
Slide 23: Corporate Responsibility
Corporate Responsibility Australian Wildlife Conservancy (AWC) Australia is the extinction capital of the world In 15 years the list of threatened species has increased by 36% 87% of Australia’s mammals, 93% of our reptiles, 94% of our frogs, and 45% of our bird species are unique to Australia www.a
Slide 24: Questions and Comments
Questions and Comments ASX: UCM Prof. Rob Phillips Chairman and CEO, Uscom Limited Oct 26, 2023
Slide 25: Thank You
Thank You ASX: UCM Prof. Rob Phillips Chairman and CEO, Uscom Limited Oct 26, 2023